June 23, 2011
Jefferson City, Mo. -- Attorney General Chris Koster said today the state of Missouri will receive $948,385 from a settlement his office and 37 other state attorneys general reached with GlaxoSmithKline, LLC (GSK) and SB Pharmco Puerto Rico (SB Pharmco). The settlement stems from allegations that GSK and SB Pharmco engaged in substandard manufacturing practices concerning several medications produced at a plant located in Cidra, Puerto Rico.
“Pharmaceutical companies will be held accountable for practices that endanger the health of consumers” Koster said. “This settlement will cause drug manufacturers to review their production practices and ensure that unsafe products are not put into the marketplace.”
Koster alleges that GSK and SB Pharmco engaged in unfair and deceptive practices when they manufactured and distributed certain batches of Kytril (a sterile drug used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy), Bactroban (an antibiotic ointment used to treat skin infections), Paxil CR (the controlled release formulation of the popular antidepressant drug, Paxil), and Avandamet (a combination Type II diabetes drug). The companies used substandard manufacturing processes in producing certain lots of these drugs. The companies will pay the states a total of $40.75 million as part of the settlement.
GSK and SB Pharmco closed their Cidra facility in 2009. As a result of the settlement, GSK and SB Pharmco are enjoined from making false, misleading or deceptive claims regarding the manufacturing of any of the type of drugs formerly manufactured at the Cidra facility.
The adulterated batches of drugs covered by this agreement have been recalled for many years. Any consumers who have questions about their medications should contact their physician or pharmacist.